[go: up one dir, main page]

BR9807339A - Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos. - Google Patents

Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos.

Info

Publication number
BR9807339A
BR9807339A BR9807339A BR9807339A BR9807339A BR 9807339 A BR9807339 A BR 9807339A BR 9807339 A BR9807339 A BR 9807339A BR 9807339 A BR9807339 A BR 9807339A BR 9807339 A BR9807339 A BR 9807339A
Authority
BR
Brazil
Prior art keywords
piperidyl
derivatives
pharmaceutical compositions
regulate
ldl
Prior art date
Application number
BR9807339A
Other languages
English (en)
Inventor
Motohide Sato
Takeo Katsuhima
Hajime Kinoshita
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of BR9807339A publication Critical patent/BR9807339A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

DENDO OS MESMOS"<D>. São providos derivados de 3-pla fórmula (I): onde R representa um grupo amino oum dos quais é substituído com um grupo arila subsu não, ou semelhante, n é um inteiro de 1 à 4, R~ 3~ e R~ 4~ representam, independentemente, um átomo de hidrogênio, um grupo alquila inferior ou semelhante, ou um sal farmaceuticamente aceitável do mes compostos não apenas inibem a formação de LDL, m também regulam a TG, o colesterol e as lipoproteínas, tais como, LDL no sangue e regulam os lipídeos celulares através da normalização da atividade de MTP. Eles também podem ser usados como um novo iperlipemia ou doenças arterioscleróticas. Adicionalmente, eles podem ser usados como agenets terapêuticos ou preventivos para pancreatite, obesidade, hipercolesterolemia e hipertrigliceridemia.
BR9807339A 1997-12-12 1998-12-11 Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos. BR9807339A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP36281997 1997-12-12
JP10288979A JP2959765B2 (ja) 1997-12-12 1998-10-12 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
PCT/JP1998/005628 WO1999031085A1 (fr) 1997-12-12 1998-12-11 Derives du 3-piperidyl-4-oxoquinazoline et compositions medicinales les contenant

Publications (1)

Publication Number Publication Date
BR9807339A true BR9807339A (pt) 2000-03-21

Family

ID=26557408

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9807339A BR9807339A (pt) 1997-12-12 1998-12-11 Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos.

Country Status (18)

Country Link
US (1) US6235730B1 (pt)
EP (1) EP0970954A4 (pt)
JP (1) JP2959765B2 (pt)
KR (1) KR20000070983A (pt)
CN (1) CN1252068A (pt)
AR (1) AR009212A1 (pt)
AU (1) AU717963B2 (pt)
BR (1) BR9807339A (pt)
CA (1) CA2280705A1 (pt)
HU (1) HUP0001154A3 (pt)
ID (1) ID23439A (pt)
IL (1) IL131319A0 (pt)
NO (1) NO993868L (pt)
NZ (1) NZ337118A (pt)
PE (1) PE20000054A1 (pt)
SK (1) SK109399A3 (pt)
TR (1) TR199901933T1 (pt)
WO (1) WO1999031085A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767739B2 (en) 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
USPP12295P2 (en) * 1999-06-01 2001-12-18 Florfis Ag Geranium plant named ‘Fiscoral’
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
JP2003104971A (ja) * 1999-08-12 2003-04-09 Wakunaga Pharmaceut Co Ltd 新規アニリド誘導体又はその塩及びこれを含有する医薬
WO2001056990A2 (en) * 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
BR0210616A (pt) 2001-06-28 2004-09-28 Pfizer Prod Inc Indóis, benzofuranos e benzotiofenos substituìdos com triamida, composição farmacêutica, uso dos referidos compostos, bem como processo para preparação dos mesmos
CN1630629B (zh) 2002-02-28 2010-05-05 日本烟草产业株式会社 酯化合物及其医药用途
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
EA200600737A1 (ru) * 2003-10-08 2006-10-27 Эли Лилли Энд Компани Соединения и способы для лечения дислипидемии
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7378426B2 (en) * 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
EP1806149A4 (en) * 2004-10-25 2012-12-05 Japan Tobacco Inc SOLID MEDICINAL PREPARATION IMPROVED IN TERMS OF SOLUBILITY AND STABILITY AND METHOD FOR PRODUCING SAME
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007056388A2 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
EP2018863B9 (en) 2006-05-16 2015-02-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
EP2041181B1 (en) * 2006-06-08 2011-05-18 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Specific protease inhibitors and their use in cancer therapy
CA2663436A1 (en) * 2006-10-04 2008-04-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
US8735391B2 (en) * 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
WO2014102592A2 (en) 2012-12-27 2014-07-03 Purdue Pharma L.P. Oxime/substituted quinoxaline-type piperidine compounds and uses thereof
WO2018033918A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1583753A (en) * 1976-07-14 1981-02-04 Science Union & Cie Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
US4364954A (en) 1980-01-10 1982-12-21 Warner-Lambert Company Diphenylpropanamines, compositions thereof and use thereof
CA2091102C (en) 1992-03-06 2009-05-26 John R. Ii Wetterau Microsomal triglyceride transfer protein
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JPH08151377A (ja) 1994-11-25 1996-06-11 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
DE69529849T2 (de) 1995-06-07 2003-09-04 Pfizer Inc., New York Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6-yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion
DE19546918A1 (de) 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide

Also Published As

Publication number Publication date
ID23439A (id) 2000-04-20
CA2280705A1 (en) 1999-06-24
AU1506899A (en) 1999-07-05
AU717963B2 (en) 2000-04-06
US6235730B1 (en) 2001-05-22
WO1999031085A1 (fr) 1999-06-24
TR199901933T1 (xx) 2000-03-21
EP0970954A4 (en) 2001-01-10
EP0970954A1 (en) 2000-01-12
JP2959765B2 (ja) 1999-10-06
JPH11228569A (ja) 1999-08-24
SK109399A3 (en) 2000-01-18
KR20000070983A (ko) 2000-11-25
AR009212A1 (es) 2000-04-12
NO993868L (no) 1999-10-12
HUP0001154A3 (en) 2001-06-28
IL131319A0 (en) 2001-01-28
NZ337118A (en) 2000-03-27
NO993868D0 (no) 1999-08-11
CN1252068A (zh) 2000-05-03
HUP0001154A2 (hu) 2001-04-28
PE20000054A1 (es) 2000-02-09

Similar Documents

Publication Publication Date Title
BR9807339A (pt) Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos.
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BR9806413A (pt) Composto e uso do mesmo
EP1362846A4 (en) AMINOETHANOL DERIVATIVES
BR9910124A (pt) Tienilazolilalcóxietanaminas, suas preparações e suas aplicações como medicamentos
NO308736B1 (no) 1,2-difenylpyrrolderivater, farmasøytiske preparater inneholdende disse, og deres anvendelse
BR9713884A (pt) Benzamida heterociclicamente substituìda, usos da mesma e de cetobenzamidoaldeìdos desta, e, preparação medicamentosa.
BR9813390A (pt) Composto, processo para a preparação do mesmo, e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, processo para efetuar a imunossupressão
ATE226574T1 (de) 4,6-diarylpyrimidin-derivate und deren salze
DE69935718D1 (de) Antidiabetische medikamente
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
NO964059D0 (no) 5H-indeno[1,2-bÅpyrazin-2,3-dionderivater, deres fremstilling samt medikamenter inneholdende forbindelsene
FR2800735B1 (fr) Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation
ES2096073T3 (es) Derivado de benzamida.
BR0213417A (pt) Compostos e composições de tetraciclicazaindóis e indolinas tendo atividade de 5-ht e seus usos
BR9814376A (pt) Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &amp;4ß1, e, resina
ATE184593T1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
BR0115454A (pt) Composto de 1-metilcarbapenem ou um sal ou derivado de éster deste farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou de um sal ou derivado de éster deste farmaceuticamente aceitável
BR9910637A (pt) Composto da série da benzofuroxana usada para distúrbios cardiovasculares, processos para a preparação dos derivados de benzofuroxana, e para a preparação de 5 (6)-[(2,3-diidróxi propilóxi)-carbonil] benzofuroxana, uso do composto, composição farmacêutica, processo para a preparação da mesma, e, processo para o tratamento de um mamìfero, incluindo um ser humano, de doença cardìacas da coronária.
ATE374366T1 (de) Aminophenoxyacetamid derivate und diese enthaltende pharmazeutische zusammensetzungen
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.
NO20000423D0 (no) Tiazolobenzoheterocykler, deres fremstilling samt medikamenter inneholdende forbindelsene
ES528455A0 (es) Procedimiento de preparacion de nuevos derivados de piperidina y sus sales de adicion acidas y amonicas cuaternarias
BR9712763A (pt) Derivados de benzenosulfonamida e medicamentos que contêm tais derivados
HUP0300573A2 (hu) Amid-típusú triazolszármazékok és ezeket tartalmazó gyógyszerkészítmények

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A,5A,6A,7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1886 DE 27/02/2007.